Acute renal failure with the combined use of rosuvastatin and fenofibrate
- 20 May 2010
- journal article
- case report
- Published by Taylor & Francis in Renal Failure
- Vol. 32 (5) , 633-635
Abstract
Among the lipid-lowering drugs, the statins and fibrates are the most commonly used agents. Either class of drug is considered relatively safe. Though a variety of albeit uncommon adverse side effects have been observed with both classes, most of these therapeutic complications can be managed without discontinuation of the offending drug. Sometimes, especially in patients with extremely high cholesterol and/or triglyceride levels, a combination regimen is deemed necessary. However, the combined use of lipid-lowering drugs increases the incidence and severity of adverse events. In this article, we report an unusual case of acute renal failure (ARF) in a patient who had been prescribed both a statin (rosuvastatin) and a fibrate (fenofibrate).Keywords
This publication has 13 references indexed in Scilit:
- Fenofibrate-Induced Acute Renal Failure Due to Massive Rhabdomyolysis after Coadministration of Statin in Two PatientsInternal Medicine, 2008
- Risks Associated With Statin TherapyCirculation, 2006
- Clinical Perspectives of Statin-Induced RhabdomyolysisThe American Journal of Medicine, 2006
- An Assessment of Statin Safety by Muscle ExpertsThe American Journal of Cardiology, 2006
- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trialThe Lancet, 2005
- Applicability of Cholesterol-Lowering Primary Prevention Trials to a General PopulationArchives of internal medicine (1960), 2001
- Rhabdomyolysis and Acute Renal Failure after Changing Statin-Fibrate CombinationsCardiology, 2000
- Drug Treatment of Lipid DisordersNew England Journal of Medicine, 1999
- Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent ItraconazoleNew England Journal of Medicine, 1995
- HMG-CoA Reductase Inhibitors for Treatment of HypercholesterolemiaNew England Journal of Medicine, 1988